Cullinan Therapeutics Statistics
Total Valuation
CGEM has a market cap or net worth of $1.34 billion. The enterprise value is $1.01 billion.
| Market Cap | 1.34B |
| Enterprise Value | 1.01B |
Important Dates
The last earnings date was Thursday, August 6, 2026, before market open.
| Earnings Date | Aug 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CGEM has 64.35 million shares outstanding. The number of shares has increased by 2.26% in one year.
| Current Share Class | 64.35M |
| Shares Outstanding | 64.35M |
| Shares Change (YoY) | +2.26% |
| Shares Change (QoQ) | +1.70% |
| Owned by Insiders (%) | 1.23% |
| Owned by Institutions (%) | 87.57% |
| Float | 48.08M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 97.79 |
| PB Ratio | 4.12 |
| P/TBV Ratio | 4.15 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.42, with a Debt / Equity ratio of 0.01.
| Current Ratio | 8.42 |
| Quick Ratio | 8.29 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -50.30% and return on invested capital (ROIC) is -7,446.87%.
| Return on Equity (ROE) | -50.30% |
| Return on Assets (ROA) | -31.36% |
| Return on Invested Capital (ROIC) | -7,446.87% |
| Return on Capital Employed (ROCE) | -68.64% |
| Weighted Average Cost of Capital (WACC) | 4.12% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.91M |
| Employee Count | 109 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +170.50% in the last 52 weeks. The beta is -0.02, so CGEM's price volatility has been lower than the market average.
| Beta (5Y) | -0.02 |
| 52-Week Price Change | +170.50% |
| 50-Day Moving Average | 17.22 |
| 200-Day Moving Average | 13.70 |
| Relative Strength Index (RSI) | 71.66 |
| Average Volume (20 Days) | 609,461 |
Short Selling Information
The latest short interest is 10.25 million, so 15.93% of the outstanding shares have been sold short.
| Short Interest | 10.25M |
| Short Previous Month | 10.29M |
| Short % of Shares Out | 15.93% |
| Short % of Float | 21.33% |
| Short Ratio (days to cover) | 16.88 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -221.81M |
| Pretax Income | -204.69M |
| Net Income | -208.34M |
| EBITDA | -221.49M |
| EBIT | -221.81M |
| Earnings Per Share (EPS) | -$3.47 |
Balance Sheet
The company has $334.54 million in cash and $2.07 million in debt, with a net cash position of $332.47 million or $5.17 per share.
| Cash & Cash Equivalents | 334.54M |
| Total Debt | 2.07M |
| Net Cash | 332.47M |
| Net Cash Per Share | $5.17 |
| Equity (Book Value) | 321.75M |
| Book Value Per Share | 5.00 |
| Working Capital | 301.35M |
Cash Flow
In the last 12 months, operating cash flow was -$159.25 million and capital expenditures -$49,000, giving a free cash flow of -$159.30 million.
| Operating Cash Flow | -159.25M |
| Capital Expenditures | -49,000 |
| Depreciation & Amortization | 316,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -159.30M |
| FCF Per Share | -$2.48 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CGEM does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.26% |
| Shareholder Yield | -2.26% |
| Earnings Yield | -15.60% |
| FCF Yield | -11.93% |
Analyst Forecast
The average price target for CGEM is $32.36, which is 55.06% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $32.36 |
| Price Target Difference | 55.06% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |